Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prevalence of antiplatelet therapy in patients with diabetes.

Miller SR, Littenberg B, MacLean CD.

Cardiovasc Diabetol. 2005 Dec 1;4:18.

2.

Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus.

Bulatova NR, Yousef AM, AbuRuz SM.

Thromb Res. 2007;121(1):43-50. Epub 2007 Apr 25.

PMID:
17462716
3.

Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada.

Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, Majumdar SR.

Clin Ther. 2004 Mar;26(3):439-46.

PMID:
15110137
4.

Adding pharmacists to primary care teams increases guideline-concordant antiplatelet use in patients with type 2 diabetes: results from a randomized trial.

Gilani F, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Spooner R, Simpson SH.

Ann Pharmacother. 2013 Jan;47(1):43-8. doi: 10.1345/aph.1R552. Epub 2013 Jan 16.

PMID:
23324512
5.

[Cardiovascular disease in patients with type 1 and type 2 diabetes in Spain].

Ortega E, Amor AJ, Rojo-Martínez G, Castell C, Giménez M, Conget I.

Med Clin (Barc). 2015 Sep 21;145(6):233-8. doi: 10.1016/j.medcli.2014.10.017. Epub 2015 Jan 2. Spanish.

PMID:
25561182
6.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

7.

Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.

Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6.

PMID:
15871850
8.

Antiplatelet therapy in patients with diabetes mellitus.

Grove EL, Gregersen S.

Curr Vasc Pharmacol. 2012 Jul;10(4):494-505. Review.

PMID:
22272895
9.

[Do we adequately prescribe antiplatelet treatment to type 2 diabetic patients?].

Gallego Arenas A, Novella Arribas B, Sierra García B, Ruiz Díaz L, Rodríguez Salvanés F; Nombre del Grupo SIRVA 2.

Semergen. 2012 Sep;38(6):360-5. doi: 10.1016/j.semerg.2012.02.001. Epub 2012 Apr 18. Spanish.

PMID:
22935832
10.

High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.

Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM.

Diabetes Care. 2006 Apr;29(4):798-804.

PMID:
16567818
11.

Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.

Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, Radican L.

Curr Med Res Opin. 2010 Jul;26(7):1697-703. doi: 10.1185/03007995.2010.489029.

PMID:
20465367
12.

Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.

Robinson JG, Booth B.

J Clin Lipidol. 2010 Nov-Dec;4(6):483-90. doi: 10.1016/j.jacl.2010.10.002. Epub 2010 Oct 13.

13.

Antiplatelet therapy in type 2 diabetes mellitus.

Angiolillo DJ.

Curr Opin Endocrinol Diabetes Obes. 2007 Apr;14(2):124-31. Review.

PMID:
17940430
14.
15.

Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.

Bai JW, Boulet G, Halpern EM, Lovblom LE, Eldelekli D, Keenan HA, Brent M, Paul N, Bril V, Cherney DZ, Weisman A, Perkins BA.

Cardiovasc Diabetol. 2016 Jan 25;15:14. doi: 10.1186/s12933-015-0318-9.

16.

Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.

Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA.

CMAJ. 2004 Nov 9;171(10):1189-92.

17.

Does diabetes have a protective effect on migraine?

Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K, Lund A.

Epidemiology. 2013 Jan;24(1):129-34. doi: 10.1097/EDE.0b013e31827623d0.

PMID:
23211346
18.

The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial.

Lewis BL, Pearce LA, Field TS, White CL, Benavente OR; SPS3 Investigators.

Int J Stroke. 2014 Jun;9(4):443-8. doi: 10.1111/ijs.12267. Epub 2014 Mar 24.

20.

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators.

Circulation. 2008 Oct 14;118(16):1626-36. doi: 10.1161/CIRCULATIONAHA.108.791061. Epub 2008 Aug 31.

Supplemental Content

Support Center